Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
TECX Sales of Investments
Cash received from selling or redeeming investments.
Tectonic Therapeutic, Inc.NASDAQ: TECX
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments outflow grows to $0
Q1 FY2026 sales of investments was $0, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $0.
Context
- Sales of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How TECX compares with its peers on the latest reported figures
- TECX's LTM Mar 2026 sales of investments of $0 is the smallest of the 4 companies compared; the peer median is $285.01M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $765.04M | +47.0% | +117.2% | — | |
GENBGenerate Biomedicines, Inc. | FY2025 | $285.01M | +24.6% | — | 893.7% |
SEPNSepterna, Inc. | LTM Sep 2026 | $268.7M | +47.4% | — | 279.1% |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TECX) | $285.01M | +47.0% | +117.2% | 586.4% | |
Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.93M) | (32.18K) | (42.82M) | (57.98M) | (74.15M) |
| Depreciation & Amortization | 364K | 1.01K | 1.48M | 1.65M | 1.38M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 639K | 1.12K | 1.12M | 3.49M | 10.5M |
| Change in Working Capital | 1.92M | (7.4M) | (584K) | (10.28M) | (70K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.45M | (3.1M) | (165K) | (1.42M) | 116K |
| Other Working Capital | 464K | (4.3M) | (419K) | (8.86M) | (186K) |
| Other Non-Cash Items | (6.45M) | (89.78M) | 127K | 4.04M | 2.27M |
| Operating Cash Flow | (12.45M) | (97.21M) | (40.68M) | (59.08M) | (60.08M) |
| Capital Expenditures | (2.12M) | (267K) | (279K) | (156K) | (208K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.12M) | (267K) | (279K) | (156K) | (138K) |
| Debt Repayment | 3.61M | (393K) | (499K) | (475K) | (489K) |
| Common Stock Issued | 2K | 262K | 34.13M | 94.6M | 174.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 393K | 121K | 77.59M | (485K) |
| Financing Cash Flow | 41.42M | 262K | 33.75M | 171.71M | 173.36M |
| Effect of Forex Changes | 0 | 492K | 16K | (8K) | (95K) |
| Net Change in Cash | 26.84M | (96.72M) | (7.2M) | 112.47M | 113.04M |
| Free Cash Flow | (14.58M) | (97.48M) | (40.96M) | (59.24M) | (60.29M) |
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Intrinsic Alpha fair value
Locked
Current Price
$21.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.